ATHE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

1 Analyst Rating

Wall Street analysts forecast ATHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHE is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Canaccord

Speculative Buy

initiated

$A1.6c

2025-12-17

Reason

Canaccord

Price Target

$A1.6c

2025-12-17

initiated

Speculative Buy

Reason

Canaccord initiated coverage of Alterity Therapeutics with a Speculative Buy rating and $A1.6c price target. Alterity is developing ATH434 for the treatment of synucleinopathy-driven neurodegenerative diseases such as multiple system atrophy and Parkinson's disease, the analyst tells investors in a research note. The firm says ATH434 addresses an unmet need.

Maxim Group

Jason McCarthy

Strong Buy

Maintains

$8 → $12

2025-01-30

Reason

Maxim Group

Jason McCarthy

Price Target

$8 → $12

2025-01-30

Maintains

Strong Buy

Reason

Maxim analyst Jason McCarthy raised the firm's price target on Alterity Therapeutics to $12 from $8 and keeps a Buy rating on the shares after the company reported Phase 2 data for lead asset ATH434 in patients with early-stage multiple system atrophy. The data are "mixed but overall positive," says the analyst, who adds that the relatively small trial should inform the design of a later-stage study.

Valuation Metrics

The current forward P/E ratio for Alterity Therapeutics Ltd (ATHE.O) is -3.81, compared to its 5-year average forward P/E of -19.03. For a more detailed relative valuation and DCF analysis to assess Alterity Therapeutics Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-19.03

Current PE

-3.81

Overvalued PE

82.48

Undervalued PE

-120.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.82

Current EV/EBITDA

-2.73

Overvalued EV/EBITDA

0.75

Undervalued EV/EBITDA

-2.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.46

Current PS

0.00

Overvalued PS

17.44

Undervalued PS

1.47

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ATHE News & Events

Events Timeline

No data

News

9.0

2025-10-31Newsfilter

Alterity Therapeutics: Q1 FY26 Cash Flow Report - Appendix 4C

9.0

2025-10-09Newsfilter

Alterity Therapeutics Showcases Encouraging Results from ATH434 Phase 2 Trial at the 2025 International Congress on Parkinson's Disease and Movement Disorders

9.0

2025-10-02Newsfilter

Alterity Therapeutics to Present Several Talks at the 2025 International Congress on Parkinson's Disease and Movement Disorders

People Also Watch

Frequently Asked Questions

What is Alterity Therapeutics Ltd (ATHE) stock price today?

The current price of ATHE is 3.52 USD — it has increased 5.71 % in the last trading day.

What is Alterity Therapeutics Ltd (ATHE)'s business?

Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

What is the price predicton of ATHE Stock?

What is Alterity Therapeutics Ltd (ATHE)'s revenue for the last quarter?

Alterity Therapeutics Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Alterity Therapeutics Ltd (ATHE)'s earnings per share (EPS) for the last quarter?

Alterity Therapeutics Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Alterity Therapeutics Ltd (ATHE)'s fundamentals?

The market is revising No Change the revenue expectations for ATHE for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -17.95%.

How many employees does Alterity Therapeutics Ltd (ATHE). have?

Alterity Therapeutics Ltd (ATHE) has 9 emplpoyees as of January 10 2026.

What is Alterity Therapeutics Ltd (ATHE) market cap?

Today ATHE has the market capitalization of 63.62M USD.